# Oxford BioMedica plc 3.3% potential upside indicated by Liberum Capital

- Link: https://www.directorstalkinterviews.com/oxford-biomedica-plc-3.3-potential-upside-indicated-by-liberum-capital/4121129107
- Published: 2023-10-10T11:48:37+01:00
- Author: Charlotte Edwards

**Oxford BioMedica plc** with ticker (LON:OXB) now has a potential upside of 3.3%
according to Liberum Capital.
Liberum Capital set a target price of 310 GBX for 
the company, which when compared to the Oxford BioMedica plc share price of 300 
GBX at opening today (10/10/2023) indicates a potential upside of 3.3%. Trading 
has ranged between 237 (52 week low) and 575 (52 week high) with an average of 229,614
shares exchanging hands daily. The market capitalisation at the time of writing 
is £295,166,007.Oxford Biomedica Plc is a United Kingdom-based viral vector specialist
that is primarily focused on delivering therapies to patients. The Company and its
subsidiaries are engaged in viral vector delivery systems, including those based
on lentivirus, adeno-associated virus (AAV) and adenovirus. It provides solutions
to cell and gene therapy biotechnology and biopharma companies for their process
development, analytical development and manufacturing needs. The Company has built
a LentiVector platform, which is focused on a lentiviral vector delivery system.
The Company is engaged in working on programs from the pre-clinical to commercial
stages across a range of therapeutic areas with global partners. The Company has
manufacturing, laboratory and office space across six facilities in Oxford, United
Kingdom. The Company’s subsidiary, Oxford Biomedica Solutions LLC, has an AAV manufacturing
facility near Boston, Massachusetts, the United States.

Share on: